GlassScriptPhysician profile
Marc Thomas Roth
NPI 1619364213
$11,733.31
in general payments reported to CMS, 2019-2025
20 companies · $6,536 in 2025
The $6,536 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $593 · 2022: $324 · 2023: $35.34 · 2024: $4,110 · 2025: $6,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $327 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,335.00 |
| Food and Beverage | $326.64 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,240.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,057.05 | 2024-2025 | Fruzaqla |
| Astrazeneca Pharmaceuticals LP | $2,055.00 | 2024 | |
| Medtronic, INC. | $331.67 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $252.91 | 2020-2021 | |
| Foundation Medicine, INC. | $202.16 | 2021 | |
| Caris Mpi, INC. | $140.24 | 2025 | Mi Cancer Seek |
| Histosonics, INC. | $139.18 | 2025 | |
| Janssen Biotech, INC. | $98.06 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.29 | 2021-2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $32.40 | 2021-2024 | |
| Celgene Corporation | $31.64 | 2022-2023 | Pomalyst |
| Acrotech Biopharma INC. | $25.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2021 | |
| Glaxosmithkline, LLC. | $22.04 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $16.50 | 2021 | |
| Seagen INC. | $16.43 | 2021 | |
| Genzyme Corporation | $13.13 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.